[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:undifferentiated-soft-tissue-sarcoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":35,"states":36},"Undifferentiated Soft Tissue Sarcoma",4,[7,15,22,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07283731","Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced\u002FMetastatic Soft-tissue Sarcoma",[11],"Phase 2","RECRUITING","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:27.740604Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT05918640","Lurbinectedin in FET-Fused Tumors",[19],"Phase 1\u002FPhase 2","2026-08-26T02:19:19.975067Z","2026-05-05T02:43:26.725098Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[19],"2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":33,"content_modified":34},"NCT04995003","HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma",[32],"Phase 1","2026-08-26T02:16:31.714843Z","2026-05-05T02:43:27.987147Z",[],[]]